Directory Image
This website uses cookies to improve user experience. By using our website you consent to all cookies in accordance with our Privacy Policy.

Creative Biolabs’ Innovative Solutions Power Macrophages Entering CAR Immunotherapy

Author: Candy Swift
by Candy Swift
Posted: Mar 07, 2022

For several years, chimeric antigen receptor (CAR) T cell therapy has been a hot issue in tumor treatment, and since it faces obstacles in solid tumors, CAR macrophage therapy has emerged as a new therapy aimed at enhancing CAR cells' capacity to target solid tumors.

Creative Biolabs has amassed a variety of knowledge in TCR and CAR-T&NK cell immunotherapy development over the years, and has established an unrivaled CAR design and construction platform across four CAR generations. It now offers the industry-leading Chimeric Antigen Receptor Macrophage (CAR-MA) services for solid tumor therapy to a worldwide reach.

  • CAR Design & Construction

Creative Biolabs has designed a novel macrophage gene transfer strategy to overcome the gene engineering challenges of employing macrophages in adoptive cell treatments, which makes CAR-MA gain a desired anti-tumor phenotype as well as resistance to tumor-induced subversion.

  • CAR-MA Preparation Service

Supported by a wealth of experience in choosing virus vectors with fine-tuning and molecular adjustments, Creative Biolabs offers reliable sources of macrophages, covering induced pluripotent stem cells (iPSC), human monocytic cell line (THP-1), human primary macrophages (CD14+ peripheral blood), and murine macrophages (Raw264.7, J774A.1).

  • Macrophages Activation and Expansion Service

The scientist team is fully aware of the complex macrophage activation process, involving the coordinate/synergistic action of signals from cytokines, chemokines, and pathogen-associated molecular patterns (PAMPs), and is dedicated to providing innovative solutions for CAR-MA activation and expansion to advance the development of CAR-MA-based immunotherapies.

"Based on current research, CAR-macrophage therapy remains very promising in solid tumor treatment, and our mission is clear, to offer great products and great service to support your pursuit of a healthier world," as introduced by a senior scientist at Creative Biolabs.

Apart from the aforementioned services, the whole pipeline of CAR-MA services also includes target identification & selection, high-affinity antigen binder generation, in vitro assessments, and preclinical tests and clinical trials. More information can be reached on https://www.creative-biolabs.com/car-t/.

About Creative Biolabs

With years of exploration in biotechnology, Creative Biolabs has gathered talented scientists working closely with worldwide partners to develop and produce medicines of tomorrow. Specifically, Creative Biolabs specializes in one-stop custom services for CAR-T cell development, TCR modified T cell development, CAR-macrophage therapy development, cancer vaccine development, drug discovery for CRS management, etc.

About the Author

Candy Swift: Focus on the cutting edge biological information around the world.

Rate this Article
Leave a Comment
Author Thumbnail
I Agree:
Comment 
Pictures
Author: Candy Swift
Professional Member

Candy Swift

Member since: Nov 06, 2019
Published articles: 187

Related Articles